Pfizer Inc.

Oncology and Hematologic Malignancies

Breast cancer, non-small cell lung cancer, small cell lung cancer, prostate cancer, and colorectal cancer are central areas of interest, alongside studies in ovarian cancer, head and neck squamous cell carcinoma, esophageal cancer, hepatocellular carcinoma, and bladder cancer. Research also extends to blood cancers such as multiple myeloma, diffuse large B-cell lymphoma, follicular lymphoma, acute lymphoblastic leukemia, and advanced lymphomas.

  • HER2-negative and hormone receptor-positive breast cancer
  • Advanced solid tumors
  • Relapsed or refractory multiple myeloma
  • Diffuse large B-cell lymphoma
  • Metastatic castration-resistant prostate cancer

Additional oncology work includes melanoma, non-muscle invasive bladder cancer, liposarcoma, and neuroblastoma, with a strong emphasis on advanced and metastatic disease settings.

Inflammatory and Autoimmune Disorders

Clinical research spans rheumatoid arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, idiopathic inflammatory myopathies, and juvenile idiopathic arthritis. The portfolio also includes immune-mediated skin and bowel diseases such as atopic dermatitis, alopecia areata, vitiligo, ulcerative colitis, Crohn’s disease, and eosinophilic esophagitis.

  • Atopic dermatitis
  • Vitiligo
  • Ulcerative colitis
  • Rheumatoid arthritis
  • Systemic lupus erythematosus

Other immune-focused studies address chronic spontaneous urticaria, hidradenitis suppurativa, and immune-mediated inflammatory disorders affecting skin, joints, and gastrointestinal tissues.

Hematology, Bleeding Disorders, and Cardiovascular Disease

Key hematology programs involve hemophilia A, hemophilia B, and primary immune thrombocytopenia, with attention to inherited bleeding disorders across pediatric and adult populations. Cardiovascular research includes heart failure, heart failure with preserved ejection fraction, and pulmonary arterial hypertension.

  • Hemophilia A
  • Hemophilia B
  • Primary immune thrombocytopenia
  • Heart failure with preserved ejection fraction
  • Pulmonary arterial hypertension

Additional areas include transthyretin amyloidosis and transthyretin amyloid cardiomyopathy, reflecting interest in rare cardiovascular and systemic protein-aggregation disorders.

Infectious Diseases and Vaccines

Pfizer’s infectious disease portfolio includes studies in COVID-19, RSV infection, pneumococcal infections, group B streptococcus disease, and serious gram-negative bacterial infections. Research also covers hospital-acquired pneumonia, ventilator-associated pneumonia, sepsis, and complicated urinary tract infection.

  • Respiratory syncytial virus
  • Group B streptococcus
  • Pneumococcal disease
  • Gram-negative bacterial infections
  • COVID-19

Vaccine-oriented work includes maternal and infant immunization studies, with emphasis on neonatal protection and prevention of invasive bacterial and respiratory infections.

Neurology, Metabolic, and Other Therapeutic Areas

Neurology studies focus on migraine, including chronic migraine, menstrual migraine, and migraine with or without aura, as well as prevention in adolescents. Metabolic and supportive-care research includes obesity, overweight management, type 2 diabetes mellitus, and cancer cachexia.

  • Migraine disorders
  • Obesity and overweight management
  • Type 2 diabetes mellitus
  • Cancer cachexia
  • Growth hormone deficiency

Other areas of interest include duchenne muscular dystrophy, IgA nephropathy, obesity-related appetite loss, and erosive esophagitis, showing breadth across neuromuscular, renal, gastrointestinal, and metabolic conditions.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Lorlatinib for Patients with ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer Continuing from Previous Studies

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain
  • Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

    Not recruiting

    3 1 1 1
    Austria Belgium Bulgaria Czechia Finland France +9
  • Study on the Efficacy and Safety of Fidanacogene Elaparvovec Gene Therapy in Adult Males with Moderate to Severe Hemophilia B

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium France Germany Greece Italy Spain +1
  • Study on the Safety and Antitumor Effects of Vepdegestrant and Abemaciclib in Adults with ER+ Advanced or Metastatic Breast Cancer

    Not recruiting

    1 1 1 1
    Italy Spain
  • Study on the Safety and Antitumor Activity of ARV-471 and Ribociclib in Adults with ER+ Advanced or Metastatic Breast Cancer

    Not recruiting

    1 1 1 1
    Italy Spain
  • Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Belgium France Germany Italy Poland Slovakia +2